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Abstract
Background—We recently reported that the skin sympathetic nerve activity (SKNA) can be used 
to estimate the sympathetic tone in humans. In animal models, vagal nerve stimulation (VNS) can 
damage the stellate ganglion, reduce stellate ganglion nerve activity and suppress cardiac 
arrhythmia. Whether or not VNS can suppress sympathetic tone in humans remain unclear.
Objective—To test the hypothesis that VNS suppresses SKNA in patients with drug resistant 
epilepsy.
Methods—We used electrocardiogram (ECG) patch electrodes to continuously record SKNA in 
26 patients with drug resistant epilepsy who were admitted for video electroencephalographic 
monitoring. Among them, 6 (2 men, age 40±11 years) were previously treated with VNS and 20 (7 
men, age 37±8 years) did not. The signals from ECG leads I and II were filtered to detect SKNA.
Results—The VNS had an ON-time of 30 s and OFF-time of 158±72 s, with output of 1.92±0.42 
mA at 24.17±2.01 Hz. The average SKNA (aSKNA) during VNS OFF-time was 1.06 μV [95% 
confidence interval, CI, 0.93 to 1.18] in lead I and 1.13 μV [CI, 0.99 to 1.27] in lead II, which was 
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significantly lower than 1.38 μV [CI, 1.01 to 1.75, p=0.036] and 1.38 μV [CI, 0.98 to 1.78, 
p=0.035] of the control Group, respectively. The heart rate was 65 bpm [CI, 59 to 71] in VNS 
group, significantly lower than 77 bpm [95% CI, 71 to 83] in control group.
Conclusion—Patients with VNS had significantly lower SKNA than patients without VNS.
Keywords
Autonomic nervous system; neuromodulation; sudden unexpected death in epilepsy
Introduction
Vagal nerve stimulation (VNS) is commonly used to manage patients with drug resistant 
epilepsy and has been reported to reduce the incidence of sudden unexpected death in 
epilepsy (SUDEP).1, 2 Recent studies showed that there is significant interictal cardiac 
electrical instability (elevated T wave alternans) in patients with drug-resistant epilepsy, 
which was effectively suppressed by VNS.3 Because T wave alternans is enhanced by 
sympathetic activation,4 these findings suggest that VNS might be associated with reduced 
sympathetic tone. Consistent with that hypothesis, Clancy et al5 reported that non-invasive 
stimulation of the auricular branch of the vagal nerve suppressed muscle sympathetic nerve 
activity in normal human volunteers. However, as far as we know, there was no study that 
demonstrated reduced sympathetic nerve activity in patients with chronically implanted 
vagal nerve stimulators. The cervical and thoracic vagal nerves contain significant 
sympathetic components.6, 7 In ambulatory dogs, left cervical VNS could be associated with 
high rate of activation of the left stellate ganglion.8 Repeated high rate of excitation might 
cause neurotoxicity and promote neuronal cell death.9 Consistent with the neurotoxicity 
hypothesis, we recently reported that there was significant damage to the left stellate 
ganglion in dogs receiving chronic VNS.10 The stellate ganglion damage was associated 
with a significant reduction of the stellate ganglion nerve activity and ventricular rate in 
atrial fibrillation (AF). However, it is difficult to record the stellate ganglion nerve activity in 
humans. We recently developed a new method (neuECG) to simultaneously record the skin 
sympathetic nerve activity (SKNA) and electrocardiogram (ECG) in ambulatory 
dogs.11, 12, 13 and in humans.14 The purpose of the present study was to record SKNA from 
patients with drug resistant epilepsy to test the hypothesis that the SKNA is lower in patients 
with VNS than in patients without VNS.
Methods
This research protocol was approved by the Institutional Review Boards of the Indiana 
University (IU) School of Medicine. We prospectively enrolled 26 patients with drug 
resistant epilepsy to participate in the study. All patients were recruited after they were 
admitted to the Epilepsy Monitoring Unit of the IU-Methodist Hospital to record video 
electroencephalogram. As part of the standard care, anti-epileptic medications were 
completely or partially withdrawn while the patients were confined to bed with bathroom 
privileges. The recordings were made continuously except when the patients went to the 
bathroom. The neuECG was recorded using standard ECG patch electrodes connected to a 
modified ME6000 (Biomation, Almonte, Ontario) recorder with a wide bandwidth (2 KHz) 
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and high sampling rate (10 KHz). All 26 patients had at least 24-hr of recording (Table 1). 
Among them, six had previously underwent VNS implantation, while 20 did not receive it. 
The standard VNS protocol was 30 s on and 3–5 min off.15 Because this is an observational 
study, the off-time was variable based on the clinical needs. The baseline SKNA of 19 
patients in the latter group was included in a previous report.14 A total of 8 patients had 
seizure during the recording period. We excluded the data recorded 40-min before to 40-min 
after the seizure from analyses.
Data Analysis
Because VNS causes large artifacts on the neuECG recording, we only analyzed data during 
the VNS-off time. The data were analyzed with a custom written software which selected 
the R waves and calculated the RR intervals and heart rate automatically. All selections were 
then confirmed by manual examination to exclude artifacts. The average SKNA (aSKNA) 
and heart rate were determined for 2 min at the beginning, 20-min past and 40-min past the 
hour for 24 hours, resulting in 72 data points per patient. If the patient went to the bathroom 
during the analyses window, we used the data acquired after the resumption of recording for 
analyses. We bandpass filtered the recorded neuECG signals between 200 Hz to 1000 Hz 
and also between 500 Hz to 1000 Hz to display SKNA. As shown in our previous report,14 
the sensitivity of detecting SKNA is higher with the former filter setting but the specificity is 
higher with the latter filter setting. The same signals were bandpass filtered between 0.5 Hz 
and 150 Hz to display the surface ECG. For quantitative analyses, we integrated all digitized 
SKNA signals over each 1-min window and divided the results (in μV) by the number of 
samples in that window (10,000 × 60, or 60,000 samples) to obtain the aSKNA. The 
quantitative analyses were done for both filter settings. The aSKNA included both the signal 
and noise. The noise level of the recording device (recorded when the two poles were 
shorted) is 1.17 μV (bandpass 200–1000 Hz) and 0.74 μV (bandpass 500–1000 Hz). Because 
vagal nerve stimulation is unlikely to change the noise level, the differences between VNS 
group and control group are due to the differences of nerve activity. Heart rate was 
determined in the same 2-min windows, resulting in 72 data points per patient. The average 
heart rate of these 72 data points were used as the heart rate for that patient.
Statistical Analysis
Linear regression was used to study the relationship between heart rate and SKNA activity 
for each patient. Linear mixed-effects models were used to compare SKNA activity between 
control and VNS stimulation groups where patients were treated as random effects. 
Generalized additive mixed-effects models were used to characterize the circadian pattern. T 
test was used to compare average SKNA activities and heart rate (over 24-hour period), and 
the correlation coefficients between SKNA and heart rate. Two-sided p values ≤0.05 were 
considered statistically significant.
Results
The VNS group included 6 patients (2 men, age 40±11 years). The control group included 
20 patients (7 men, age 37±8 years) (Table 1). None of the patients had cardiovascular 
diseases. The admission diagnoses were generalized tonic-clonic seizure (N=1), complex 
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partial seizure with secondarily generalized tonic-clonic seizure (N=2) and complex partial 
seizure (N=3) in VNS group; generalized tonic-clonic seizure (N=6), complex partial seizure 
with secondarily generalized tonic-clonic seizure (N=6) and complex partial seizure (N=8) 
in control group. Patients in the VNS group had received VNS treatment for an average of 
81±39 months (range 20 to 121 months). VNS was programmed to an ON-time of 30 s and 
OFF-time of 158±72 s. The output was 1.92±0.42 mA with a frequency of 24.17±2.01 Hz.
Patterns of SKNA in control group
Figure 1 shows a typical example of SKNA episodes recorded in a patient without VNS. The 
SKNA can be either prolonged or episodic. Panel A shows a prolonged nerve discharge 
episode associated with heart rate acceleration. The data from the red rectangles are enlarged 
and shown in Panel B. Panel C shows short bursts of SKNA which were also associated with 
heart rate elevation. The data from the red rectangles were enlarged and shown in Panel D. 
These SKNA episodes were not pulse synchronous and were morphologically similar to that 
recorded from the superficial branches of radial nerves with microneurography techniques.16 
The artifacts on surface ECG (red dots) suggest that some of the SKNA episodes occurred 
coincidentally with the physical activity.
Patterns of SKNA in VNS group
As compared with patients in control group, the VNS group had reduced SKNA episodes. 
Figure 2A shows SKNA and heart rate in control patient who had an active SKNA and 
corresponding heart rate elevation. Similar episodes were rare in VNS patients. When 
present, the SKNA were also associated with heart rate changes. The VNS episodes 
typically interrupts the SKNA episode and reduces the heart rate variations (Figure 2B). In 
most patients with VNS, the SKNA episodes were infrequently observed. Supplement 
Figure 1 shows a longer term (5-min) recording from a VNS patient (Panel A) and a control 
patient (Panel B). In VNS Patient, there were very low amplitudes of SKNA during the VNS 
ON and OFF times, with only little heart rate variations. In comparison, a control patient had 
high SKNA activity and robust heart responses to SKNA.
Correlation between heart rate and SKNA
There was a positive correlation between heart rate and SKNA in all patients studied. We 
tested the correlation using two different filter settings for SKNA detection. For all patients 
studied, the average Pearson’s correlation coefficients between aSKNA (200 Hz–1000 Hz 
bandpass filter) and heart rate was 0.52 [CI, 0.39 to 0.65] in VNS group, and 0.72 [CI, 0.65 
to 0.79, p=0.024] in control group. The correlation coefficients were 0.45 [CI, 0.35 to 0.56] 
in VNS group, and 0.60 [CI, 0.43 to 0.66, p=0.019] in control group after 500 Hz–1000 Hz 
bandpass filtering. Supplement Figure 2 shows the typical examples of the correlation 
between heart rate and aSKNA in both groups of patients. A total of 144 dots were in each 
graph. Panel A and B were obtained a after bandpass filtering between 200 Hz and 1000 Hz. 
Panel C and D were obtained a after bandpass filtering between 500 Hz and 1000 Hz. Each 
dot represents the average with a 1-min window.
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Circadian variation of SKNA
Figure 3 summarizes hourly averaged aSKNA over a 24-hour period from lead I (Panels A 
and B) and lead II (Panels C and D) in all patients studied. With either filter setting, the 
aSKNA of patients in the VNS group for both filter settings was significantly (p<0.00001) 
lower than the aSKNA in patients of the control group. In both VNS and control groups, 
aSKNA showed significant (p<0.00001) circadian variations.
Comparison of aSKNA between control group and VNS group
Figure 4 shows the range of aSKNA in Lead I, Lead II and heart rate of all patients studied. 
The control group had significantly higher aSKNA and heart rate than the VNS group. When 
bandpass filtered between 200 Hz and 1000 Hz, the aSKNA during VNS OFF-time was 2.44 
μV [95% confidence interval, CI, 2.13 to 2.74] in lead I and 2.49 μV [CI, 2.05 to 2.94] in 
lead II in the VNS group. These aSKNA values were significantly lower than 3.72 μV [CI, 
2.58 to 4.87, p=0.012] and 3.26 μV [CI, 2.14 to 4.39, p=0.014], respectively, of the control 
Group. When filtered between 500 Hz and 1000 Hz, the aSKNA during VNS OFF-time was 
1.06 μV [CI, 0.93 to 1.18] in lead I and 1.13 μV [CI, 0.99 to 1.27] in lead II, which were 
significantly lower than 1.38 μV [CI, 1.01 to 1.75, p=0.036] and 1.38 μV [CI, 0.98 to 1.78, 
p=0.035], respectively, of the control Group. The average heart rate was 65 bpm [CI, 59 to 
71] in VNS group and 77 bpm [CI, 72 to 83] in the control group (p=0.013). The average 
systolic blood pressure of VNS patients and non-VNS patients were 116±10 mmHg and 
127±16 mmHg, respectively (p=0.1369). The average diastolic blood pressure of VNS 
patients and non-VNS patients were 69±6 mmHg and 75±10 mmHg, respectively 
(p=0.1807).
Because patients with hypertension may have heightened sympathetic tone,17 we removed 
patients with hypertension and repeated the analyses of the remaining patients (5 with VNS 
and 14 without VNS). Using 200–1000 Hz filter setting, the aSKNA in Lead I was 2.41 μV 
(CI 2.01 to 2.80) in VNS group and 3.81 μV (CI 3.36 to 4.27) in non-VNS group (p=0.023). 
The aSKNA in Lead II was 2.37 μV (CI 1.96 to 2.78) in VNS group and 3.64 μV (CI 2.79 to 
4.49) in non-VNS group (p=0.001). Using 500–1000 Hz filter setting, the aSKNA in Lead I 
was 1.02 μV (CI 0.92 to 1.12) in VNS group and 1.69 μV (CI 1.29 to 2.09) in non-VNS 
group (p=0.049). The aSKNA in Lead II was 1.08 μV (CI 1.04 to 1.12) in VNS group and 
1.57 μV (CI 1.34 to 1.81) in non-VNS group (p=0.015). Therefore, excluding hypertensive 
patients did not change the conclusion of the study.
Discussion
The results of the present study show that patients with left VNS had lower heart rate and 
aSKNA than patients without VNS. These findings suggest that chronic intermittent VNS 
can reduce sympathetic tone in humans.
Vagal nerve stimulation and cardiovascular diseases
VNS is a well-established therapeutic option for patients with drug resistant epilepsy18, 19 
but also had significant effects on cardiovascular function. Studies in animal models showed 
that VNS might be helpful in managing acute ischemia and in prolonging survival in heart 
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failure,20–23 although recent clinical trials failed to confirm those findings.24 Another 
potential application of VNS in heart diseases is in the rate and rhythm control of 
AF.10, 25, 26 VNS has been reported to reduce the incidence of sudden unexpected death in 
epilepsy (SUDEP),1, 2 but others failed to confirm that finding.27
Mechanisms of VNS
The vagal nerve is a complex anatomical structure. It is generally accepted that 
parasympathetic activation is responsible for some of the therapeutic effects of VNS. 
However, if parasympathetic activation is responsible for heart rate control, then the 
therapeutic effects of the VNS should be limited only to the time when VNS is turned on. 
When VNS is turned off, ventricular conduction should accelerate, leading to a loss of 
therapeutic benefit. Recordings in ambulatory dogs showed that the ventricular responses 
during AF was reduced even when VNS was off.10 One possibility for this carry over effect 
is that stimulation of the sympathetic component in the vagal nerve may activate the 
ganglion cells in the SG at high rates,8 which may cause neurotoxicity,9 damages stellate 
ganglion to reduce the stellate ganglion nerve activity. In addition to interacting with the 
stellate ganglion, VNS also targets convergent local circuit neurons of the intrinsic cardiac 
nervous system to mitigate the potential for neurally induced AF.28
Skin sympathetic nerve recording
The skin is well innervated by sympathetic nerve fibers.29, 30 The somata of the nerves in the 
upper extremities and thorax resides in the cervical and stellate ganglia.31 Our recent studies 
showed that SKNA could be detected in humans using conventional patch electrodes using a 
recording system with high sampling rate and wide frequency bandwidth.32, 33 High pass 
filtering could eliminate the ECG signals and retain high frequency signals that included 
both muscle and nerve activities. Like most diagnostic tests, specificity could be increased 
only at the cost of reduction in sensitivity and vice versa. A wider bandpass filter setting 
(200 Hz to 1000 Hz) allowed us to increase the sensitivity of detecting SKNA but reduced 
specificity because the frequency of muscle activities could reach 400 Hz.34 A narrow 
bandpass filter setting (500 Hz to 1000 Hz) was more specific but might be less sensitive in 
detecting the SKNA. We have therefore used both filter settings to detect nerve activity in 
the present study. With either filter setting, we were able to document robust SKNA in 
control patients and reduced SKNA in patients with VNS. These findings suggest that, 
similar to VNS in ambulatory dogs,10 VNS in humans also suppresses sympathetic tone and 
maybe potentially useful in cardiac arrhythmia control.
SKNA and heart rate
The heart rate is controlled by both sympathetic and parasympathetic nerve activities. While 
the SKNA is a useful measure of sympathetic tone, it does not adequately measure all nerve 
activities that control the sinus node. Therefore, the average correlation coefficient between 
aSKNA and heart rate was around 0.45–0.72 in different groups and using different filter 
settings. Similar correlation coefficients were also observed between sympathetic nerve 
activities and heart rate in ambulatory dogs.11 It is unclear why VNS patients had reduced 
heart rate responses to SKNA. However, because VNS may damage the stellate ganglion and 
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reduce sympathetic outflow,10 the damaged stellate ganglion might not be able to generate 
enough sympathetic tone to overcome the parasympathetic influence of the sinus node.
Limitations of the study
We do not have the histological sections or direct recordings of the stellate ganglion in 
patients with VNS. Therefore, it is not possible to determine if VNS has caused stellate 
ganglion damage or a reduction of stellate ganglion nerve activity. None of the patients died 
suddenly or had significant arrhythmias during the recording. Therefore, the relationship 
between SKNA and SUDEP remains unclear. The electrode impedance was not measured in 
the present study. However, we have previously reported that the average impedance of the 
electrodes as the one used in the present study was 37 ± 8 kΩ (range 28–52 kΩ).32
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Figure 1. 
Patterns of baseline SKNA. All data were obtained from ECG Lead I. A shows persistent 
SKNA associated with heart rate acceleration. The digitized signals were bandpass between 
500–1000 Hz to display the high frequency nerve activities. The integrated SKNA of Lead I 
(iSKNA-I) display the sum of SKNA over each 100 ms window, which is a common method 
to display nerve activities in microneurography studies.35 The same signals from ECG Lead 
I were bandpass filtered from 0.5 to 150 Hz to display surface ECG. Note the artifact on 
ECG (red dot) suggests physical activity at the beginning of the episode. B shows the data in 
the two red boxes of A in greater detail. C shows short bursts of SKNA associated with 
corresponding heart rate elevation (arrows). D shows the data in the two red boxes of C in 
greater detail. (SKNA=skin sympathetic nerve activity, iSKNA= integrated skin sympathetic 
nerve activity, ECG= electrocardiogram.)
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Figure 2. 
Effects of VNS on nerve activities. A shows recording made on ECG Lead I in a control 
patient. There were nerve discharges associated with episodic heart rate elevation (arrows). 
Persistent SKNA occurred towards the end of the recording. B shows a recording from VNS 
patient. Note that there were intermittent episodic SKNA prior to VNS, but no SKNA after 
VNS. These intermittent heart rate elevations were noted prior to VNS, corresponding to the 
SKNA episodes. Little heart rate variations were noted after VNS (red bar). (SKNA=skin 
sympathetic nerve activity, iSKNA= integrated skin sympathetic nerve activity, ECG= 
electrocardiogram.)
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Figure 3. 
Hourly averaged nerve activities from Lead I and II in all patients studied. A and B show 
SKNA from Lead I while C and D show SKNA from Lead II. The filter settings are labeled 
in each panel. With either filter setting, the aSKNA was higher in the control group than in 
the VNS group. A significant circadian variation was noted in each graph. (Lead I: average 
SKNA at ECG Lead I. Lead II: average SKNA at ECG Lead II).
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Figure 4. 
Average skin sympathetic nerve activities (aSKNA) and heart rate recorded of all patients 
studied. Each dot represents the aSKNA of a patient over a 24-hr period. A and B: The 
SKNA was bandpass filtered between 200 Hz to 1000 Hz. D and E: The SKNA was 
bandpass filtered between 500 Hz to 1000 Hz. C: Heart rate of both groups. F: Correlation 
coefficients of the Pearson’s correlation test of both groups. Horizontal bars represent mean 
and 95% confidence interval. *: p<0.05. (aSKNA-I: average skin sympathetic nerve activity 
at ECG Lead I. aSKNA-II: average skin sympathetic nerve activity at ECG Lead II)
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